Description
Detralex Pharmacodynamics
Detralex® has venotonic and angioprotective properties.
The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to the indices of venous hemodynamics.
Statistically reliable dose-dependent effect of the drug Detralex® has been demonstrated for the following venous plethysmographic parameters? venous capacity, venous distensibility, and time of venous emptying. An optimal dose-effect ratio is observed when taking 1000 mg daily.
Detralex® increases venous tone: venous occlusion plethysmography has been shown to decrease the time of venous emptying. In patients with signs of a significant microcirculatory disturbance, after therapy with Detralex® an increase in capillary resistance evaluated by angiostereometry (statistically significant compared to placebo) has been noted
The therapeutic efficacy of Detralex® has been proved in the treatment of chronic diseases of lower limb veins, as well as in the treatment of hemorrhoids.
Indications
Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Therapy of symptoms of venous and lymphatic insufficiency:
– pain;
– cramps of the lower extremities;
– A feeling of heaviness and expansion in the legs;
– Leg fatigue.
Therapy of manifestations of venous and lymphatic insufficiency:
– swelling of the lower extremities;
– Trophic changes in the skin and subcutaneous tissue;
– venous trophic ulcers.
Symptomatic therapy for acute and chronic hemorrhoids.
Contraindications .
Hypersensitivity to the active components or excipients within the drug.
Pregnancy and breast-feeding (experience of use is limited or absent).
Childhood under 18 years of age (no experience of use).
Administration during pregnancy and breastfeeding
Pregnancy
There are no or limited data on the use of purified micronized flavonoid fraction in pregnant women.
Animal studies have shown no reproductive toxicity.
As a precautionary measure, it is preferable not to use Detralex® during pregnancy.
Breastfeeding period
It is not known whether purified micronized flavonoid fraction (metabolites) penetrates human breast milk.
Risks to newborns and infants cannot be excluded. A decision should be made either to stop breastfeeding or to discontinue therapy with Detralex®, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Effects on reproductive function
Studies of reproductive toxicity have shown no effect on reproductive function in rats of either sex
Dosage and administration
- Oral.
- The recommended dosage for veno-lymphatic insufficiency is 1 tablet per day, preferably in the morning, with meals. Tablets should be swallowed with water.
- The rasp on the tablet is intended solely for the division in order to facilitate swallowing.
The duration of treatment may be several months (up to 12 months). In case of recurrence of symptoms, the course of treatment may be repeated as recommended by the doctor. - The recommended dose for acute hemorrhoids – 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.
- The recommended dose for chronic hemorrhoids is 1 tablet per day.
